Sema4 went public via a SPAC merger with Casdin Capital and Corvex Management-backed CM Life Sciences in a $2bn deal.

Sema4, an AI- and machine learning-driven patient-centered genomic and clinical data intelligence company, went public via a SPAC merger with Casdin Capital and Corvex Management-backed CM Life Sciences, a SPAC, in a $2bn deal. Financing includes a fully committed PIPE of $350m from growth and life science investors including Casdin Capital, Corvex Management, Fidelity Management & Research Company, Counterpoint Global, Perceptive Advisors, SoftBank, T. Rowe Price, Viking Global Investors, Blackrock and Deerfield Management. “With the capital raised from this successful transaction, we are well positioned to help further close the gap between the practice of medicine and the availability of more clinically actionable guidance in order to improve the standard of care. We look forward to continuing to develop and scale our innovative health intelligence platform to enable health systems in delivering precision medicine as the standard of care,” Eric Schadt, Ph.D., Sema4 Founder and CEO.